Kiora Pharmaceuticals, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Brian Strem
- Full Time Employees
- 12
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1371 East 2100 South Encinitas UT United States of America 84105
- IPO Date
- Feb 13, 2015
- CIK
- 0001372514
- Website
- kiorapharma.com
- Similar Companies
- Business
- Kiora Pharmaceuticals, Inc. (Nasdaq: KPRX) is a clinical-stage pharmaceutical company focused on developing and commercializing therapies for ocular diseases, including dry eye disease, presbyopia, uveitis, glaucoma, and macular degeneration. The company offers a pipeline of investigational products such as KIO-301, a photoswitch technology for retinitis pigmentosa and other inherited retinal diseases; KIO-102, a next-generation ebselen for dry eye disease and diabetic macular edema; KIO-105, a toll-like receptor inhibitor for presbyopia; KIO-201, a synthetic anti-inflammatory for post-cataract surgery inflammation and pain; KIO-206, a pan-TRPV1 antagonist for ocular surface pain; KIO-301, for vision restoration in blind patients; and KIO-104, for non-infectious uveitis. These products target anterior and posterior segment disorders through small molecule, biologic, and gene therapy modalities. Founded in 2002 and headquartered in Encinitas, California, Kiora operates primarily in the United States with clinical trials conducted globally. In the past 1-2 years, Kiora has advanced its pipeline through key milestones, including positive topline results from the Phase 2b ARDA trial for KIO-301 in late 2024, demonstrating sustained vision improvement in patients with retinitis pigmentosa; initiation of the Phase 2 LUCID-202 trial for KIO-102 in dry eye disease in early 2025; and the completion of enrollment in the Phase 2b Manzil trial for KIO-104 in uveitis announced in mid-2025. The company secured a $15 million registered direct offering in March 2025 to fund clinical development and operations; entered a strategic collaboration with Laboratoires Théa in 2024 for European commercialization rights to select pipeline assets; and expanded its manufacturing partnerships for API production of KIO-102 ahead of planned Phase 3 trials. These developments reflect Kiora's shift toward late-stage clinical execution and international market preparation, with no subsidiaries or parent entities reported.
Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway
Financial Comparison: Cronos Group (NASDAQ:CRON) & Kiora Pharmaceuticals (NASDAQ:KPRX)
Kiora Pharmaceuticals Announces Management Team Changes
Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical Trials
Kiora Pharmaceuticals to Present at Oppenheimer's 36th Annual Healthcare Life Sciences Conference
Financial Review: Kiora Pharmaceuticals (NASDAQ:KPRX) & Stevanato Group (NYSE:STVN)
Retinal Disease Expert Dr. Taiji Sakamoto Joins Kiora Pharmaceuticals' Scientific Advisory Board
Kiora Pharmaceuticals Granted U.S. Patent Covering Additional Formulations for the KIO-100 Family of Anti-Inflammatory Compounds
Kiora Pharmaceuticals Reports Third Quarter 2025 Results; Company Advances Pipeline with Two Actively Enrolling Phase 2 Clinical Trials for Retinal Diseases
Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New Treatments for Rare Ocular Disorders
Kiora Pharmaceuticals to Participate in the 2025 Maxim Growth Summit and Eyecelerator @ AAO 2025
Kiora (KPRX) Q2 Revenue Falls 100%
Kiora Pharmaceuticals Reports Second Quarter 2025 Results; Company Advances Pipeline with Two Active Phase 2 Clinical Trials for Retinal Diseases
Kiora Pharmaceuticals Granted U.S. Patent Expanding Protection for KIO-104 in the Treatment of Ocular Disease
Kiora Pharmaceuticals (KPRX) Upgraded to Strong Buy: Here's What You Should Know
Kiora Pharmaceuticals and Senju Pharmaceutical Partner on KIO-301 for the Treatment of Retinal Diseases in Asia
Kiora Pharmaceuticals Reports First Quarter Results; Initiating Two Phase 2 Trials for Treatment of Retinal Diseases; Cash and Short-term Investments Expected to Fund Operations into Late 2027
Kiora Pharmaceuticals to Present at The 24th Annual Needham Virtual Healthcare Conference
Kiora Pharmaceuticals Reports 2024 Results; Retinal Disease Drug Development Pipeline Continues to Advance; Cash and Short-Term Investments Expected to Fund Operations into 2027